Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Prokidney (PROK) over the last 3 years, with Sep 2025 value amounting to $95.3 million.

  • Prokidney's Cash & Equivalents fell 11.81% to $95.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.3 million, marking a year-over-year decrease of 11.81%. This contributed to the annual value of $99.1 million for FY2024, which is 63.43% up from last year.
  • As of Q3 2025, Prokidney's Cash & Equivalents stood at $95.3 million, which was up 12.22% from $84.9 million recorded in Q2 2025.
  • Prokidney's Cash & Equivalents' 5-year high stood at $506.3 million during Q3 2022, with a 5-year trough of $60.6 million in Q4 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $99.1 million (2024), whereas its average is $141.0 million.
  • In the last 5 years, Prokidney's Cash & Equivalents crashed by 87.63% in 2023 and then spiked by 63.43% in 2024.
  • Over the past 4 years, Prokidney's Cash & Equivalents (Quarterly) stood at $490.3 million in 2022, then plummeted by 87.63% to $60.6 million in 2023, then surged by 63.43% to $99.1 million in 2024, then fell by 11.81% to $95.3 million in 2025.
  • Its Cash & Equivalents stands at $95.3 million for Q3 2025, versus $84.9 million for Q2 2025 and $97.8 million for Q1 2025.